Homotaurine: A failed drug for Alzheimer's disease and now a nutraceutical for memory protection

American Journal of Health-System Pharmacy

Volumn 66, Issue 21, 2009, Pages 1950-1953

  Swanoski, Michael T ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Duluth Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINESTERASE INHIBITOR; ESTROGEN; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; MEMANTINE; NEUROLEPTIC AGENT; NUTRACEUTICAL; PLACEBO; SEDATIVE AGENT; TAU PROTEIN; UNCLASSIFIED DRUG; VIVIMIND;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; COGNITION; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FALLING; HUMAN; LIQUORRHEA; MEMORY; NAUSEA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 70449623037     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080576     Document Type: Note

References (30)

1. Moran M. Cost of bringing new drugs to market rising rapidly. Psychiatr News. 2003; 38:25.
2. Bellus Health. Bellus Health reports results for third quarter of fiscal 2008 and on EMEA update. http://innodia-inc.com/news-archive/en/news/2008-11-110 php (accessed 2009 Jan 30).
3. Herbert LE, Scherr PA, Bienias JL et al. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60:1119-1122
4. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005; 331:321-327 (Pubitemid 41113141)
5. Raina P, Santaguida P, Ismaila A et al. Effectiveness of Cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008; 148:379-97. (Pubitemid 351665469)
6. Walker LC, Ibegbu CC, Todd CW et al. Emerging prospects for the disease-modifying treatment of Alzheimer's disease. Biochem Pharmacol. 2005; 69:1001-8.
7. American Association for Geriatric Psychiatry. AAGP position statement: principles of care for patients with dementia resulting from Alzheimer disease. www.aagponline.org/prof/position-caredmnalz.asp (accessed 2008 Apr 26).
8. Schmidt R, Ropele S, Pendl B et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry. 2008; 79:1312-1317
9. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19:989-996
10. Holcomb L, Gordon MN, McGowan E et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998; 4:97-100.
11. Näslund J, Haroutunian V, Mohs R et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000; 283:1571-7. (Pubitemid 30161512)
12. Nagy Z, Esiri MM, Jobst KA et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia. 1995; 6:21-31.
13. Lewis I, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001; 293:1487-1491
14. Götz J, Chen F, van Dorpe J et al. Formation of neurofibrillary tangles in P301I tau transgenic mice induced by Abeta 42 fibrils. Science. 2001; 293:1491-1495 (Pubitemid 32807681)
15. Love R. Untangling the relation between β-amyloid and tau. Lancet. 2001; 358:645. News.
16. OVOS Natural Health. Vivimind information. www.vivimind.com/information. aspx (accessed 2009 Jan 30).
17. Alzheimer Research Forum. Drugs in clinical trials. www.alzforum.org/drg/ drc/detail.asp?id=84 (accessed 2009 Jan 30).
18. Gervais F, Chalifour R, Garceau D et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001; 8(suppl 1):28-35. (Pubitemid 32889453)
19. Gervais F. GAG mimetics: potential to modify underlying disease process in AD. Neurobiol Aging. 2004; 25(suppl 2):S11-2.
20. Aisen PS, Saumier D, Briand R et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006; 67:1757-1763 (Pubitemid 44900749)
21. Bellus Health. Neurochem announces results from tramiprosate (Alzhemed) North American Phase III clinical trial. www.bellushealth.com/en/newsroom/?rkey= 1508262369&view=96347-2&Start=0 (accessed 2009 Jul 23).
22. Alzheimer Research Forum. FDA deems U.S. Alzhemed trial results inconclusive. www.alzforum.org/new/detail.asp?id=1647 (accessed 2008 Jun 6).
23. Santa-Maria I, Hernández F, Del Rio J et al. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener. 2007; 2:17. (Pubitemid 350046026)
24. Silcoff S. A memory drug by any other name. www.financialpost.com/ analysis/columnist/story.html?id=934555cf-fcd2-4c49-804c-2d7e6cc65878&k= 81018 (accessed 2009 Jul 23).
25. Moss K, Boon H, Ballantyne P et al. New Canadian natural health product regulations: a qualitative study of how CAM practitioners perceive they will be impacted. BMC Complement Altern Med. 2006; 6:18. (Pubitemid 43933652)
26. Koren G, Oren D, Rouleau M et al. Comparison of verbal claims for natural health products made by health food stores staff versus pharmacists in Ontario, Canada. Can J Clin Pharmacol. 2006; 13:e251-6. (Pubitemid 44406022)
27. Agriculture and Agri-Food Canada. Functional foods and nutraceuticals. www4.agr.gc.ca/AAFC-AAC/display-afficher.do?id=1170856376710&lang=eng (accessed 2009 Jan 30).
28. Bull E, Rapport L, Lockwood B. What is a nutraceutical? Pharm J. 2000; 265:57-58
29. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. J Gen Intern Med. 2008; 23:854-859
30. Alzheimer Research Forum. Experts slam marketing of tramiprosate (Alzhemed) as nutraceutical. www.alzforum.org/new/detail.asp?id=1937 (accessed 2008 Oct 24).